CO51 Safety Profile of Approved Alzheimer's Medication By USFDA

ADRD will affect 6.7 million Americans aged 65+ in 2023, expected to double by 2050. Pharmacological management includes two symptomatic approaches: inhibition of acetylcholinesterase (donepezil, galantamine, rivastigmine) and N-methyl-D-aspartate receptors. Recommended treatments are AChEIs for mild-moderate AD.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research